Capri Holdings Ltd vs Revvity Inc — how do they compare? Capri Holdings Ltd trades at $15.71 (market cap $1.75B), while Revvity Inc trades at $116.47 (market cap $12.91B). The key difference: Revvity Inc is far larger — about 7.4× Capri Holdings Ltd's market cap, and Revvity Inc pays a 0.24% dividend while Capri Holdings Ltd pays none. Which is the better fit depends on your goals.
| CPRI | RVTY | |
|---|---|---|
Market Cap | $1.75B | $12.91B |
Sector | Consumer Staples | Technology |
52-Week High | $27.66 | $117.75 |
52-Week Low | $14.98 | $82.26 |
Enterprise Value | $3.03B | $15.23B |
Dividend Yield | — | 0.24% |
Signals from Pluang's Aura AI — not financial advice
Capri Holdings (CPRI) trades at $15.47, near its 52-week low, with a bearish technical outlook and recent earnings beats overshadowed by declining revenue and a net loss of $1.18 billion in 2025. The company faces challenges in its core Michael Kors brand, with revenue forecasts cut and a high debt-to-asset ratio of 28.79% as of 2025. Despite a consensus price target of $19.60, analyst sentiment is mixed, with 44% buy ratings but significant hold recommendations.
The stock's investment appeal hinges on a successful turnaround, with potential upside from margin improvements and Jimmy Choo growth, but risks include persistent revenue declines, luxury market softness, and execution uncertainties. Near-term volatility is likely as the company navigates brand revamps and inventory issues.
RVTY trades at $116.10, up 0.07% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The company reported Q2 2026 EPS of $1.41, surpassing the $1.21 estimate, and raised its full-year outlook due to robust diagnostics demand. Revenue remains steady around $2.9 billion, with a net income margin of 8.16%. Analyst consensus is a Buy with a $120.50 price target, and recent news highlights product launches like the SuperFlex prenatal system and high-throughput TB testing platform.
The outlook for RVTY is positive, supported by earnings momentum and strategic innovations, but investors face risks from high valuation multiples and competitive pressures in the healthcare sector. The stock's proximity to its consensus target suggests limited near-term upside, requiring careful monitoring of execution against raised guidance.
Trailing returns across standard periods
Michael Kors, Versace, and Jimmy Choo are the brands of Capri Holdings, a marketer, distributor, and retailer of upscale accessories and apparel. Kors, Capri's largest brand, offers handbags, footwear, and apparel through more than 800 company-owned stores, wholesale, and e-commerce. Versace (acquired in 2018) is known for its ready-to-wear luxury fashion, while Jimmy Choo (acquired in 2017) is best known for women's luxury footwear. John Idol has served as CEO since 2003.
Read more on CPRI →Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →